[
  {
    "ts": null,
    "headline": "Cencora Inc. stock outperforms competitors on strong trading day",
    "summary": "Cencora Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=3ce7bcb6a8e285710dcc5733a3c4d609a020349a8c767f0a7ea20e6122bd469a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770828300,
      "headline": "Cencora Inc. stock outperforms competitors on strong trading day",
      "id": 139065407,
      "image": "",
      "related": "COR",
      "source": "MarketWatch",
      "summary": "Cencora Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=3ce7bcb6a8e285710dcc5733a3c4d609a020349a8c767f0a7ea20e6122bd469a"
    }
  },
  {
    "ts": null,
    "headline": "5 Revealing Analyst Questions From Cencora’s Q4 Earnings Call",
    "summary": "Cencora's fourth quarter was marked by a negative market reaction, as revenue missed Wall Street’s expectations despite year-over-year growth. Management attributed performance to continued growth in its U.S. healthcare solutions, particularly specialty pharmaceuticals and new contributions from recent acquisitions. CEO Robert Mauch emphasized the impact of enhanced operational capabilities and highlighted the integration of Retina Consultants of America (RCA) and the completion of the OneOncolo",
    "url": "https://finnhub.io/api/news?id=6ce97f17930c481c237f87d80e01fecbfc007d215d28027f6d141a4d9f395072",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770788172,
      "headline": "5 Revealing Analyst Questions From Cencora’s Q4 Earnings Call",
      "id": 139042413,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Cencora's fourth quarter was marked by a negative market reaction, as revenue missed Wall Street’s expectations despite year-over-year growth. Management attributed performance to continued growth in its U.S. healthcare solutions, particularly specialty pharmaceuticals and new contributions from recent acquisitions. CEO Robert Mauch emphasized the impact of enhanced operational capabilities and highlighted the integration of Retina Consultants of America (RCA) and the completion of the OneOncolo",
      "url": "https://finnhub.io/api/news?id=6ce97f17930c481c237f87d80e01fecbfc007d215d28027f6d141a4d9f395072"
    }
  }
]